We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Neurology

Journal Scan / Research · August 01, 2021

Migraine Prophylaxis: Rimegepant vs Placebo, Erenumab, and Galcanezumab



Additional Info

Disclosure statements are available on the authors' profiles:

Matching-Adjusted Indirect Comparisons of Oral Rimegepant Versus Placebo, Erenumab, and Galcanezumab Examining Monthly Migraine Days and Health-Related Quality of Life in the Treatment of Migraine
Headache 2021 May 22;[EPub Ahead of Print], E Popoff, K Johnston, R Croop, A Thiry, L Harris, L Powell, V Coric, G L'Italien, J Moren

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.